



Announcement on Completion of signing license agreement with NIPPON SHOKUBAI CO., LTD.

February 21, 2023
Rena Therapeutics Inc.

Rena Therapeutics Inc. (President & CEO: Shuichi Toriya, headquarters: Chiyoda-ku, Tokyo, Japan) announced today that it has executed a non-exclusive license agreement with NIPPON SHOKUBAI CO., LTD. (President: Kazuhiro Noda, headquarters: Chuo-ku, Osaka, Japan) enabling the worldwide manufacture and sale of Hetero Duplex Oligonucleotide (HDO) research reagents in countries where patents exist.

With the execution of this agreement, HDO will be widely available for trial by domestic and foreign enterprise and academia customers. HDO is a platform technology for nucleic acid medicine. For example, by binding a ligand for a receptor to the HDO carrier strand, the active strand can be selectively delivered to the target disease site through the binding of this ligand to the receptor expressed on the cell surface.

We hope that having a wide range of people in enterprises and academia try it will expand the possibilities of HDO and lead to more opportunities to use HDO.

If you would like to try HDO, please contact NIPPON SHOKUBAI, Health & Medical Business Division, Phone: 06-6317-0051 Fax: 06-6223-2217 Email: health_medical@shokubai.co.jp
HP: <https://www.shokubai.co.jp/en/lp/lifescience/>.

If you are interested in using HDO for commercial purposes such as drug discovery, you are required to sign a license agreement for the HDO patent. In that case, please contact Rena Therapeutics, Business Development Division, Ryohei Shimizu (Phone: 03-4243-6081 Email: info@renatherapeutics.com).

Outline of Rena Therapeutics Co., Ltd.

Established: January 2015 (Participated in Nippon Shokubai Group in November 2019)

Capital: 100 million yen

Representative: Shuichi Toriya, President & CEO

Location: 1-9-2 Otemachi, Chiyoda-ku, Tokyo

Business description: Provision of basic drug discovery technology related to nucleic acid medicine

Company HP: <https://www.renatherapeutics.com/>